Emerging evidence suggests that antibodies outside the classical criteria, such as anti-prothrombin/phosphatidylserine (anti-PT/PS) IgM, may contribute to thrombosis risk and could serve as additional pathogenic markers in APS. The gene discussed is F2; the disease is autoimmune polyendocrinopathy.